{"id":38971,"date":"2025-08-11T12:00:38","date_gmt":"2025-08-11T04:00:38","guid":{"rendered":"https:\/\/flcube.com\/?p=38971"},"modified":"2025-08-11T12:00:39","modified_gmt":"2025-08-11T04:00:39","slug":"johnson-johnsons-rybrevant-approved-by-chinas-nmpa-for-egfr-mutant-nsclc-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38971","title":{"rendered":"Johnson &amp; Johnson&#8217;s Rybrevant Approved by China&#8217;s NMPA for EGFR-Mutant NSCLC Treatment"},"content":{"rendered":"\n<p>US giant Johnson &amp; Johnson (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) announced that China&#8217;s National Medical Products Administration (NMPA) has approved a new indication for Rybrevant (amivantamab) in combination with Lazcluze (Lazertinib) for the treatment of patients with EGFR-mutant progressive or recurrent non-small cell lung cancer (NSCLC). This approval expands the therapeutic options for patients with this aggressive form of lung cancer.<\/p>\n\n\n\n<p><strong>Mechanism and Previous Approvals<\/strong><br>Amivantamab is an EGFR-MET bispecific antibody (BsAb) previously approved for use in combination with carboplatin and pemetrexed as a first-line treatment for locally advanced or metastatic NSCLC in adult patients with the EGFR exon 20 insertion mutation. It is also approved for use in combination with carboplatin and pemetrexed for patients with locally advanced or metastatic non-squamous NSCLC who have experienced disease progression during or after EGFR tyrosine kinase inhibitor (TKI) therapy. Lazertinib, a third-generation EGFR TKI, complements amivantamab by enhancing the suppression of disease progression in advanced NSCLC with EGFR mutations, effectively addressing the complexity and heterogeneity of acquired resistance mechanisms.<\/p>\n\n\n\n<p><strong>Clinical Trial Results<\/strong><br>The approval of this chemo-free regimen is based on the results of the Phase 3 MARIPOSA trial. Compared to osimertinib, the combination of amivantamab and lazertinib demonstrated a 30% reduction in the risk of disease progression or death, with a median progression-free survival (PFS) of 23.7 months, significantly surpassing the osimertinib group&#8217;s 16.6 months. The safety profile of the combination therapy aligns with previous reports, with adverse events predominantly graded 1-2 and occurring mainly within the first four months of treatment. Long-term follow-up has not identified any new safety signals.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US giant Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that China&#8217;s National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38972,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,29,150,149,858,15,33],"class_list":["post-38971","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-combination-therapy","tag-jj","tag-johnson-johnson","tag-nyse-jnj","tag-product-approvals","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Johnson &amp; Johnson&#039;s Rybrevant Approved by China&#039;s NMPA for EGFR-Mutant NSCLC Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US giant Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that China&#039;s National Medical Products Administration (NMPA) has approved a new indication for Rybrevant (amivantamab) in combination with Lazcluze (Lazertinib) for the treatment of patients with EGFR-mutant progressive or recurrent non-small cell lung cancer (NSCLC). This approval expands the therapeutic options for patients with this aggressive form of lung cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38971\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson &amp; Johnson&#039;s Rybrevant Approved by China&#039;s NMPA for EGFR-Mutant NSCLC Treatment\" \/>\n<meta property=\"og:description\" content=\"US giant Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced that China&#039;s National Medical Products Administration (NMPA) has approved a new indication for Rybrevant (amivantamab) in combination with Lazcluze (Lazertinib) for the treatment of patients with EGFR-mutant progressive or recurrent non-small cell lung cancer (NSCLC). This approval expands the therapeutic options for patients with this aggressive form of lung cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38971\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-11T04:00:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-11T04:00:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38971#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38971\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Johnson &amp; Johnson&#8217;s Rybrevant Approved by China&#8217;s NMPA for EGFR-Mutant NSCLC Treatment\",\"datePublished\":\"2025-08-11T04:00:38+00:00\",\"dateModified\":\"2025-08-11T04:00:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38971\"},\"wordCount\":275,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38971#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1101.webp\",\"keywords\":[\"Cancer\",\"Combination therapy\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"NYSE: JNJ\",\"Product approvals\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38971#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38971\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38971\",\"name\":\"Johnson &amp; Johnson's Rybrevant Approved by China's NMPA for EGFR-Mutant NSCLC Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38971#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38971#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1101.webp\",\"datePublished\":\"2025-08-11T04:00:38+00:00\",\"dateModified\":\"2025-08-11T04:00:39+00:00\",\"description\":\"US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that China's National Medical Products Administration (NMPA) has approved a new indication for Rybrevant (amivantamab) in combination with Lazcluze (Lazertinib) for the treatment of patients with EGFR-mutant progressive or recurrent non-small cell lung cancer (NSCLC). This approval expands the therapeutic options for patients with this aggressive form of lung cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38971#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38971\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38971#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Johnson & Johnson's Rybrevant Approved by China's NMPA for EGFR-Mutant NSCLC Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38971#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson &amp; Johnson&#8217;s Rybrevant Approved by China&#8217;s NMPA for EGFR-Mutant NSCLC Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Johnson &amp; Johnson's Rybrevant Approved by China's NMPA for EGFR-Mutant NSCLC Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that China's National Medical Products Administration (NMPA) has approved a new indication for Rybrevant (amivantamab) in combination with Lazcluze (Lazertinib) for the treatment of patients with EGFR-mutant progressive or recurrent non-small cell lung cancer (NSCLC). This approval expands the therapeutic options for patients with this aggressive form of lung cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38971","og_locale":"en_US","og_type":"article","og_title":"Johnson &amp; Johnson's Rybrevant Approved by China's NMPA for EGFR-Mutant NSCLC Treatment","og_description":"US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that China's National Medical Products Administration (NMPA) has approved a new indication for Rybrevant (amivantamab) in combination with Lazcluze (Lazertinib) for the treatment of patients with EGFR-mutant progressive or recurrent non-small cell lung cancer (NSCLC). This approval expands the therapeutic options for patients with this aggressive form of lung cancer.","og_url":"https:\/\/flcube.com\/?p=38971","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-11T04:00:38+00:00","article_modified_time":"2025-08-11T04:00:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38971#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38971"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Johnson &amp; Johnson&#8217;s Rybrevant Approved by China&#8217;s NMPA for EGFR-Mutant NSCLC Treatment","datePublished":"2025-08-11T04:00:38+00:00","dateModified":"2025-08-11T04:00:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38971"},"wordCount":275,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38971#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1101.webp","keywords":["Cancer","Combination therapy","J&amp;J","Johnson &amp; Johnson","NYSE: JNJ","Product approvals","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38971#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38971","url":"https:\/\/flcube.com\/?p=38971","name":"Johnson &amp; Johnson's Rybrevant Approved by China's NMPA for EGFR-Mutant NSCLC Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38971#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38971#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1101.webp","datePublished":"2025-08-11T04:00:38+00:00","dateModified":"2025-08-11T04:00:39+00:00","description":"US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that China's National Medical Products Administration (NMPA) has approved a new indication for Rybrevant (amivantamab) in combination with Lazcluze (Lazertinib) for the treatment of patients with EGFR-mutant progressive or recurrent non-small cell lung cancer (NSCLC). This approval expands the therapeutic options for patients with this aggressive form of lung cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38971#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38971"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38971#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1101.webp","width":1080,"height":608,"caption":"Johnson & Johnson's Rybrevant Approved by China's NMPA for EGFR-Mutant NSCLC Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38971#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Johnson &amp; Johnson&#8217;s Rybrevant Approved by China&#8217;s NMPA for EGFR-Mutant NSCLC Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38971"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38971\/revisions"}],"predecessor-version":[{"id":38973,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38971\/revisions\/38973"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38972"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}